These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 9530542)

  • 1. Meningococcal vaccines. Current status and future possibilities.
    Peltola H
    Drugs; 1998 Mar; 55(3):347-66. PubMed ID: 9530542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for the prevention of meningococcal disease: special reference to group B.
    Frasch CE
    Vaccine; 1987 Mar; 5(1):3-4. PubMed ID: 3107234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine prevention of meningococcal disease, coming soon?
    Morley SL; Pollard AJ
    Vaccine; 2001 Dec; 20(5-6):666-87. PubMed ID: 11738731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines against meningococcal disease: current and future technologies.
    Riddell A; Buttery J
    Expert Opin Biol Ther; 2001 May; 1(3):385-99. PubMed ID: 11727513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides.
    Peltola H; Safary A; Käyhty H; Karanko V; André FE
    Pediatrics; 1985 Jul; 76(1):91-6. PubMed ID: 3925430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningococcal disease: the advances and challenges of meningococcal disease prevention.
    Yogev R; Tan T
    Hum Vaccin; 2011 Aug; 7(8):828-37. PubMed ID: 21832882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.
    Trotter CL; Ramsay ME
    FEMS Microbiol Rev; 2007 Jan; 31(1):101-7. PubMed ID: 17168998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
    Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.
    Guerin PJ; Naess LM; Fogg C; Rosenqvist E; Pinoges L; Bajunirwe F; Nabasumba C; Borrow R; Frøholm LO; Ghabri S; Batwala V; Twesigye R; Aaberge IS; Røttingen JA; Piola P; Caugant DA
    PLoS Negl Trop Dis; 2008; 2(12):e342. PubMed ID: 19048025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential and limitations of polysaccharide vaccines in infancy.
    Cadoz M
    Vaccine; 1998; 16(14-15):1391-5. PubMed ID: 9711777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serogroup A meningococcal conjugate vaccines in Africa.
    Kristiansen PA; Jørgensen HJ; Caugant DA
    Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults.
    Deeks ED
    BioDrugs; 2010 Oct; 24(5):287-97. PubMed ID: 20795751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.
    Granoff DM; Gupta RK; Belshe RB; Anderson EL
    J Infect Dis; 1998 Sep; 178(3):870-4. PubMed ID: 9728562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
    MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal disease and its control with meningococcal polysaccharide vaccines.
    Galazka A
    Bull World Health Organ; 1982; 60(1):1-7. PubMed ID: 6979414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The implications of vaccines for prevention of bacterial meningitis.
    Riordan A
    Curr Opin Neurol; 2010 Jun; 23(3):319-24. PubMed ID: 20173637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.
    Blanchard-Rohner G; Pollard AJ
    Expert Rev Vaccines; 2011 May; 10(5):673-84. PubMed ID: 21604987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.